Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Appointment of President
On April 21, 2021, Cerevel Therapeutics Holdings, Inc. (the "Company") announced
that Abraham N. Ceesay has been appointed to serve as the Company's President,
effective as of May 3, 2021.
Since 2019, Mr. Ceesay served as the chief executive officer at Tiburio
Therapeutics, Inc., a biopharmaceutical company focused on the development of
novel therapies for rare neuroendocrine tumors and endocrine diseases. Prior to
joining Tiburio, from 2016 to 2018, Mr. Ceesay served as chief operating officer
at scPharmaceuticals Inc., a publicly traded pharmaceutical company. Before
joining scPharmaceuticals, from 2014 to 2016, Mr. Ceesay served as vice
president, sales & marketing operations at Keryx Biopharmaceuticals, Inc., now
Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company focused
on renal disease. Prior to Keryx, from 2010 to 2014, Mr. Ceesay served at
Ironwood Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most
recently as vice president, marketing. From 2002 to 2010, he held positions of
increasing responsibility at Sanofi Genzyme, the specialty care global business
unit of Sanofi, a publicly traded multinational pharmaceutical company, most
recently as director, renal global marketing. Mr. Ceesay currently serves as a
member of the boards of directors of Food for Free, Life Science Cares and Camp
Harbor View, each a non-profit organization. Mr. Ceesay holds a B.S. from Ithaca
College and an M.B.A. from Suffolk University's Sawyer School of Management.
Mr. Ceesay, age 43, does not have any family relationship with any director or
executive officer, or a person nominated to be a director or executive officer,
of the Company. Mr. Ceesay is not a party to any transaction with the Company
that would require disclosure under Item 404(a) of Regulation S-K, nor have any
such transactions been proposed. There are no arrangements or understandings
between Mr. Ceesay and any other person(s) pursuant to which Mr. Ceesay was
appointed as the Company's President.
Employment Agreement with Mr. Ceesay
In connection with his appointment as President, Mr. Ceesay and the Company
entered into an employment agreement, dated April 13, 2021 (the "Ceesay
Employment Agreement").
Pursuant to the terms of the Ceesay Employment Agreement, Mr. Ceesay is entitled
to a base salary of $500,000 and an annual target bonus equal to 45% of his
annual base salary. His salary is subject to increase from time to time by the
Company's board of directors in its discretion. Mr. Ceesay is eligible to
participate in the Company's benefit plans that are generally available to the
Company's senior executive employees, subject to the terms of those plans. The
Ceesay Employment Agreement also provided for a one-time cash signing bonus in
the amount of $250,000 and a promised equity award of stock options subject to
the terms of an award agreement and the Company's equity incentive plan.
Mr. Ceesay's employment has no specified term but can be terminated at will by
either party. If Mr. Ceesay's employment is terminated by the Company without
Cause, or if Mr. Ceesay terminates his employment for Good Reason (as such terms
are defined in the Ceesay Employment Agreement), Mr. Ceesay will be entitled to
certain payments and benefits in addition to accrued obligations. These payments
and benefits include (i) twelve (12) months of salary continuation, (ii) a
prorated amount of his target annual bonus for the year of such termination
based on the number of days of Mr. Ceesay's service during the year his
employment is terminated and (iii) up to twelve (12) months (dependent on COBRA
eligibility for such period) of Company-sponsored benefits continuation.
The foregoing description of the Ceesay Employment Agreement does not purport to
be complete and is qualified in its entirety by the copy thereof which is filed
as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by
reference.
Item 7.01. Regulation FD Disclosure.
On April 21, 2021, the Company issued a press release announcing Mr. Ceesay's
appointment as President. A copy of the press release is being furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
--------------------------------------------------------------------------------
The information contained in Item 7.01 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
10.1† Employment Agreement, dated April 13, 2021, by and between Cerevel
Therapeutics, LLC and Abraham N. Ceesay.
99.1 Press Release issued by Cerevel Therapeutics Holdings, Inc. on
April 21, 2021.
† Certain confidential portions (indicated by brackets and asterisks) have been
omitted from this exhibit.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses